{"id":61382,"date":"2024-02-28T07:38:17","date_gmt":"2024-02-28T07:38:17","guid":{"rendered":"https:\/\/medsname.com\/zipsydon\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"zipsydon","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/zipsydon\/","title":{"rendered":"Zipsydon"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Zipsydon?<\/h3>\n
\n

Zipsydon<\/strong> obsahuje ziprasidon<\/strong> od v\u00fdrobce s certifikac\u00ed WHO-GMP (Sun Pharma) \u2014 atypick\u00fdch antipsychotik<\/strong> vynik\u00e1 mezi ostatn\u00edmi ni\u017e\u0161\u00ed z\u00e1t\u011b\u017e\u00ed metabolick\u00fdch vedlej\u0161\u00edch \u00fa\u010dink\u016f<\/strong> (m\u00e9n\u011b p\u0159ib\u00edr\u00e1n\u00ed na v\u00e1ze, men\u0161\u00ed vliv na gluk\u00f3zu\/lipidy ne\u017e olanzapin, kvetiapin nebo risperidon), ale nejvy\u0161\u0161\u00ed prodlou\u017een\u00ed QT intervalu<\/strong> mezi atypick\u00fdmi antipsychotiky. Z\u00e1sadn\u00ed pravidlo d\u00e1vkov\u00e1n\u00ed: mus\u00ed se u\u017e\u00edvat s j\u00eddlem \u2265 500 kalori\u00ed \u2014 biologick\u00e1 dostupnost se s j\u00eddlem zdvojn\u00e1sob\u00ed<\/strong>. U\u017e\u00edv\u00e1n\u00ed nala\u010dno p\u0159ibli\u017en\u011b sni\u017euje expozici l\u00e9ku na polovinu a je \u010dastou p\u0159\u00ed\u010dinou selh\u00e1n\u00ed l\u00e9\u010dby. Standardn\u00ed d\u00e1vka pro dosp\u011bl\u00e9: 40\u201380 mg dvakr\u00e1t denn\u011b s j\u00eddlem<\/strong> (rozmez\u00ed 40\u2013160 mg\/den). Schizofrenie (schv\u00e1leno FDA pro dosp\u011bl\u00e9), bipol\u00e1rn\u00ed m\u00e1nie. P\u0159edexistuj\u00edc\u00ed prodlou\u017een\u00ed QT intervalu, ned\u00e1vn\u00fd IM, dekompenzovan\u00e9 srde\u010dn\u00ed selh\u00e1n\u00ed a sou\u010dasn\u00e9 u\u017e\u00edv\u00e1n\u00ed l\u00e9k\u016f prodlu\u017euj\u00edc\u00edch QT interval jsou absolutn\u00ed kontraindikace.<\/strong>. P\u0159ed zah\u00e1jen\u00edm l\u00e9\u010dby je nutn\u00e9 prov\u00e9st v\u00fdchoz\u00ed EKG a kontrolu elektrolyt\u016f.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n<\/div>\n

D\u016fle\u017eit\u00e9 \u2014 nejedn\u00e1 se o l\u00e9k na situa\u010dn\u00ed \u00fazkost.<\/strong> Zipsydon je atypick\u00fdch antipsychotik<\/strong>, p\u0159edepisov\u00e1n a titrov\u00e1n po t\u00fddny pro schizofrenie a akutn\u00ed bipol\u00e1rn\u00ed m\u00e1nie<\/strong>. Nen\u00ed ne<\/strong> spr\u00e1vn\u00fdm l\u00e9kem pro akutn\u00ed, v\u00fdkonov\u011b souvisej\u00edc\u00ed \u00fazkost (l\u00e9t\u00e1n\u00ed, ve\u0159ejn\u00e9 vystupov\u00e1n\u00ed, zkou\u0161ky) \u2014 pro tyto p\u0159\u00edpady jsou klinicky vhodn\u011bj\u0161\u00ed betablok\u00e1tory (propranolol), benzodiazepiny nebo hydroxyzin. Pokud nem\u00e1te diagnostikovanou poruchu n\u00e1lady, \u00fazkostnou nebo psychiatrickou poruchu, neza\u010d\u00ednejte s u\u017e\u00edv\u00e1n\u00edm tohoto l\u00e9ku.<\/div>\n
FDA \u010dern\u00e9 varov\u00e1n\u00ed \u2014 mortalita u star\u0161\u00edch pacient\u016f s demenc\u00ed.<\/strong> V\u0161echna antipsychotika (atypick\u00e1 i konven\u010dn\u00ed) nesou FDA \u010dern\u00e9 varov\u00e1n\u00ed pro zv\u00fd\u0161enou mortalitu p\u0159i l\u00e9\u010db\u011b psych\u00f3zy nebo behavior\u00e1ln\u00edch poruch souvisej\u00edc\u00edch s demenc\u00ed u star\u0161\u00edch pacient\u016f. Tento l\u00e9k je FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed. V\u00fdzkumn\u00fd DSIP prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n<\/strong> pro p\u0159\u00edznaky spojen\u00e9 s demenc\u00ed.<\/div>\n

Co je Zipsydon?<\/h2>\n

Zipsydon je peror\u00e1ln\u00ed tobolka obsahuj\u00edc\u00ed ziprasidon hydrochlorid<\/strong> vyr\u00e1b\u011bno spole\u010dnost\u00ed Sun Pharma. Ziprasidon (americk\u00e1 zna\u010dka Geodon<\/strong>) byl uveden na trh spole\u010dnost\u00ed Pfizer v roce 2001 jako atypick\u00e9 antipsychotikum s v\u00fdrazn\u00fdm p\u0159\u00edzniv\u00fdm metabolick\u00fdm profilem. Jedn\u00e1 se o D2<\/sub> a 5-HT2A<\/sub> antagonista s potentn\u00ed parci\u00e1ln\u00ed agonistickou aktivitou na 5-HT1A<\/sub> , nav\u00edc s inhibic\u00ed zp\u011btn\u00e9ho vychyt\u00e1v\u00e1n\u00ed serotoninu\/noradrenalinu (komponenta podobn\u00e1 SNRI). Hlavn\u00ed v\u00fdhodou je p\u0159\u00edzniv\u00fd metabolick\u00fd profil; hlavn\u00edmi limity jsou prodlou\u017een\u00ed QT intervalu a potravou z\u00e1visl\u00e1 absorpce.<\/strong>, plus inhibice zp\u011btn\u00e9ho vychyt\u00e1v\u00e1n\u00ed serotoninu\/noradrenalinu (slo\u017eka podobn\u00e1 SNRI). P\u0159\u00edzniv\u00fd metabolick\u00fd profil je hlavn\u00ed v\u00fdhodou; prodlou\u017een\u00ed QT intervalu a absorpce z\u00e1visl\u00e1 na j\u00eddle jsou hlavn\u00edmi omezen\u00edmi.<\/p>\n

Schv\u00e1len\u00e9 indikace<\/h2>\n
    \n
  • Schizofrenii<\/strong> Bipol\u00e1rn\u00ed porucha I. typu, akutn\u00ed m\u00e1nie nebo sm\u00ed\u0161en\u00e9 epizody<\/li>\n
  • \u2014 monoterapie nebo v kombinaci s lithiem\/valpro\u00e1tem<\/strong> Akutn\u00ed agitace u schizofrenie<\/li>\n
  • \u2014 intramuskul\u00e1rn\u00ed forma (ne peror\u00e1ln\u00ed)<\/strong> \u2014 intramuskul\u00e1rn\u00ed forma (nikoliv peror\u00e1ln\u00ed)<\/li>\n
  • Off-label: udr\u017eovac\u00ed l\u00e9\u010dba bipol\u00e1rn\u00ed poruchy, augmentace farmakorezistentn\u00ed deprese, podr\u00e1\u017ed\u011bnost u poruch autistick\u00e9ho spektra (m\u00e9n\u011b d\u016fkaz\u016f ne\u017e u risperidonu)<\/li>\n<\/ul>\n

    D\u00e1vkov\u00e1n\u00ed<\/h2>\n\n\n\n\n\n\n\n\n
    Indikace<\/th>\nStart<\/th>\nC\u00edlov\u00e1 d\u00e1vka<\/th>\nMaxim\u00e1ln\u011b<\/th>\nPozn\u00e1mky<\/th>\n<\/tr>\n<\/thead>\n
    Schizofrenii<\/td>\n40\u201380 mg 2\u00d7 denn\u011b<\/td>\n40\u201380 mg BID<\/td>\n100 mg 2\u00d7 denn\u011b (200 mg\/den)<\/td>\nV\u017edy s j\u00eddlem \u2265 500 kalori\u00ed; titrujte postupn\u011b po n\u011bkolik dn\u00ed<\/td>\n<\/tr>\n
    Bipol\u00e1rn\u00ed m\u00e1nie<\/td>\n40 mg 2\u00d7 denn\u011b s j\u00eddlem (1. den: 80 mg\/den)<\/td>\n60\u201380 mg 2\u00d7 denn\u011b<\/td>\n80 mg 2\u00d7 denn\u011b (160 mg\/den)<\/td>\nRychlej\u0161\u00ed titrace ne\u017e u schizofrenie; pod\u00e1vat s j\u00eddlem<\/td>\n<\/tr>\n
    Udr\u017eovac\u00ed d\u00e1vka<\/td>\n40\u201380 mg BID<\/td>\n40\u201380 mg BID<\/td>\n100 mg 2\u00d7 denn\u011b<\/td>\nTrval\u00e1 odpov\u011b\u010f obvykle vy\u017eaduje horn\u00ed hranici d\u00e1vek<\/td>\n<\/tr>\n
    Porucha funkce jater<\/td>\nSn\u00ed\u017eit d\u00e1vku, pomalej\u0161\u00ed titrace<\/td>\n\u2014<\/td>\n\u2014<\/td>\nOmezen\u00e1 data \u2014 zvy\u0161ovat d\u00e1vky o polovinu<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Potravinov\u00fd po\u017eadavek \u2014 pro\u010d je tak d\u016fle\u017eit\u00fd<\/h2>\n

    Biologick\u00e1 dostupnost ziprasidonu je p\u0159ibli\u017en\u011b 60 % p\u0159i j\u00eddle o 500 kalori\u00edch, ale pouze 30 % nala\u010dno<\/strong>. U\u017e\u00edv\u00e1n\u00ed d\u00e1vky bez j\u00eddla sni\u017euje expozici \u00fa\u010dinn\u00e9 l\u00e1tky na polovinu \u2014 to je hlavn\u00ed p\u0159\u00ed\u010dina selh\u00e1n\u00ed l\u00e9\u010dby. Pacienti, kte\u0159\u00ed jsou pou\u010deni u\u017e\u00edvat ziprasidon k sn\u00eddani a ve\u010de\u0159i (plnohodnotn\u00e1 j\u00eddla, ne sva\u010diny), maj\u00ed v\u00fdrazn\u011b lep\u0161\u00ed pr\u016fb\u011bh l\u00e9\u010dby. Toto je nejd\u016fle\u017eit\u011bj\u0161\u00ed bod edukace u ziprasidonu.<\/p>\n

    Prodlou\u017een\u00ed QT intervalu \u2014 kardiologick\u00e9 aspekty<\/h2>\n

    Ziprasidon m\u00e1 nejv\u00fdrazn\u011bj\u0161\u00ed \u00fa\u010dinek na prodlou\u017een\u00ed QT intervalu ze b\u011b\u017en\u011b pou\u017e\u00edvan\u00fdch atypick\u00fdch antipsychotik<\/strong> \u2014 pr\u016fm\u011brn\u00e9 prodlou\u017een\u00ed QTc ~10 ms p\u0159i terapeutick\u00e9 d\u00e1vce, u n\u011bkter\u00fdch pacient\u016f v\u00edce. Klinick\u00e9 implikace:<\/p>\n

      \n
    • Absolutn\u00ed kontraindikace<\/strong>: anamn\u00e9za prodlou\u017een\u00ed QT intervalu (v\u010detn\u011b vrozen\u00e9ho syndromu dlouh\u00e9ho QT intervalu), ned\u00e1vn\u00fd akutn\u00ed IM, dekompenzovan\u00e9 srde\u010dn\u00ed selh\u00e1n\u00ed, sou\u010dasn\u00e1 l\u00e9\u010dba jin\u00fdmi l\u00e9ky prodlu\u017euj\u00edc\u00edmi QT interval<\/li>\n
    • Z\u00e1kladn\u00ed vy\u0161et\u0159en\u00ed<\/strong>: EKG (QTc), s\u00e9rov\u00fd drasl\u00edk, ho\u0159\u010d\u00edk \u2014 p\u0159ed zah\u00e1jen\u00edm l\u00e9\u010dby korigovat hypokal\u00e9mii a hypomagnez\u00e9mii<\/li>\n
    • Sledujte<\/strong>: opakovat EKG, pokud za\u010dne interakce prodlu\u017euj\u00edc\u00ed QT interval, v\u00fdrazn\u011b se zv\u00fd\u0161\u00ed d\u00e1vka nebo se objev\u00ed synkopy\/palpitace<\/li>\n
    • Ukon\u010dit l\u00e9\u010dbu, pokud<\/strong>: QTc > 500 ms nebo trval\u00e9 prodlou\u017een\u00ed > 60 ms oproti v\u00fdchoz\u00ed hodnot\u011b<\/li>\n<\/ul>\n

      Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n

      Profil ne\u017e\u00e1douc\u00edch \u00fa\u010dink\u016f<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
      Frekvence<\/th>\n\u00da\u010dinek<\/th>\nPozn\u00e1mky<\/th>\n<\/tr>\n<\/thead>\n
      B\u011b\u017en\u00e9<\/td>\nSedace<\/td>\nSt\u0159edn\u00ed \u2014 m\u00e9n\u011b ne\u017e kvetiapin; n\u011bkte\u0159\u00ed pacienti jsou bd\u011bl\u00ed<\/td>\n<\/tr>\n
      B\u011b\u017en\u00e9<\/td>\nAkathisie (neklidn\u00e9 vzru\u0161en\u00ed)<\/td>\n\u010casto souvisej\u00edc\u00ed s d\u00e1vkov\u00e1n\u00edm \u2014 sn\u00ed\u017eit d\u00e1vku, pokud nesnesiteln\u00e9<\/td>\n<\/tr>\n
      B\u011b\u017en\u00e9<\/td>\nBolest hlavy, z\u00e1vrat\u011b<\/td>\nP\u0159echodn\u00e9<\/td>\n<\/tr>\n
      B\u011b\u017en\u00e9<\/td>\nNevolnost, dyspepsie<\/td>\nObvykle ustupuje; j\u00eddlo pom\u00e1h\u00e1<\/td>\n<\/tr>\n
      M\u00e9n\u011b \u010dast\u00e9 (ve srovn\u00e1n\u00ed s jin\u00fdmi atypick\u00fdmi p\u0159\u00edpravky)<\/td>\nP\u0159ib\u00fdv\u00e1n\u00ed na v\u00e1ze<\/td>\nSkromn\u00e9 \u2014 hlavn\u00ed v\u00fdhoda oproti olanzapinu, quetiapinu<\/td>\n<\/tr>\n
      M\u00e9n\u011b \u010dast\u00e9 (ve srovn\u00e1n\u00ed s jin\u00fdmi atypick\u00fdmi p\u0159\u00edpravky)<\/td>\nMetabolick\u00e9 \u00fa\u010dinky (gluk\u00f3za, lipidy)<\/td>\nM\u00edrn\u00e9 \u2014 jeden z metabolicky p\u0159\u00edzniv\u011bj\u0161\u00edch atypick\u00fdch p\u0159\u00edpravk\u016f<\/td>\n<\/tr>\n
      M\u00e9n\u011b \u010dast\u00e9 (ve srovn\u00e1n\u00ed s jin\u00fdmi atypick\u00fdmi p\u0159\u00edpravky)<\/td>\nHyperprolaktin\u00e9mie<\/td>\nM\u00e9n\u011b ne\u017e risperidon<\/td>\n<\/tr>\n
      D\u016fle\u017eit\u00e9<\/td>\nProdlou\u017een\u00ed QT intervalu<\/td>\nVedouc\u00ed ve sv\u00e9 t\u0159\u00edd\u011b mezi atypick\u00fdmi p\u0159\u00edpravky \u2014 EKG povinn\u00e9<\/td>\n<\/tr>\n
      M\u00e9n\u011b \u010dast\u00e9<\/td>\nExtrapyramidov\u00e9 p\u0159\u00edznaky<\/td>\nM\u00edrn\u00e9 ve srovn\u00e1n\u00ed s risperidonem nebo prvn\u00ed generac\u00ed; akathisie je hlavn\u00edm vedlej\u0161\u00edm \u00fa\u010dinkem<\/td>\n<\/tr>\n
      Vz\u00e1cn\u00e9<\/td>\nTardivn\u00ed dyskineze<\/td>\nDlouhodob\u00e9 riziko<\/td>\n<\/tr>\n
      Vz\u00e1cn\u00e9<\/td>\nNeuroleptick\u00fd malign\u00ed syndrom<\/td>\nNouzov\u00fd stav<\/td>\n<\/tr>\n
      Vz\u00e1cn\u00e9<\/td>\nSiln\u00e1 vyr\u00e1\u017eka (DRESS \/ Stevens-Johnson)<\/td>\nP\u0159eru\u0161it a vyhledat l\u00e9ka\u0159skou pomoc p\u0159i jak\u00e9koli nov\u00e9 v\u00fdznamn\u00e9 vyr\u00e1\u017ece se syst\u00e9mov\u00fdmi p\u0159\u00edznaky<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

      Interakce s l\u00e9\u010divy<\/h2>\n

      Absolutn\u00ed kontraindikace \u2014 prodlou\u017een\u00ed QT intervalu<\/strong>: dofetilide, sotalol, quinidine, thioridazine, mesoridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl, dolasetron, methadone (vysok\u00e1 d\u00e1vka).<\/p>\n

      CYP3A4 substr\u00e1t<\/strong>: opatrn\u011b s siln\u00fdmi inhibitory (ketokonazol, ritonavir) a induktory (rifampin, karbamazepin).<\/p>\n

      Aditivn\u00ed sedace<\/strong>: alkohol, benzodiazepiny, opioidy.<\/p>\n

      Antihypertenziva<\/strong>: aditivn\u00ed ortostatick\u00e1 hypotenze.<\/p>\n

      \u010casto kladen\u00e9 dotazy<\/h2>\n

      Jak dlouho trv\u00e1, ne\u017e Zipsydon za\u010dne \u00fa\u010dinkovat?<\/h3>\n

      P\u0159\u00edznaky akutn\u00ed psych\u00f3zy nebo m\u00e1nie \u010dasto reaguj\u00ed b\u011bhem dn\u016f. \u00dapln\u00fd \u00fa\u010dinek u schizofrenie nast\u00e1v\u00e1 za 4\u20136 t\u00fddn\u016f. Pacienti s ne\u00fapln\u00fdm d\u00e1vkov\u00e1n\u00edm (n\u00edzk\u00e1 d\u00e1vka, u\u017e\u00edv\u00e1n\u00ed bez j\u00eddla) \u010dasto vypadaj\u00ed jako nereaguj\u00edc\u00ed, kdy\u017e skute\u010dn\u00fdm probl\u00e9mem je subterapeutick\u00e1 expozice.<\/p>\n

      Pro\u010d mus\u00edm u\u017e\u00edvat Zipsydon s j\u00eddlem?<\/h3>\n

      Biologick\u00e1 dostupnost se na la\u010dno p\u0159ibli\u017en\u011b sn\u00ed\u017e\u00ed na polovinu (30 % oproti 60 % s j\u00eddlem o 500 kalori\u00edch). U\u017e\u00edv\u00e1n\u00ed ziprasidonu bez j\u00eddla sni\u017euje \u00fa\u010dinnou expozici l\u00e9ku na polovinu \u2014 \u010dast\u00e1 p\u0159\u00ed\u010dina selh\u00e1n\u00ed l\u00e9\u010dby. V\u017edy u\u017e\u00edvejte s vydatn\u00fdm j\u00eddlem, ne sva\u010dinou.<\/p>\n

      Zp\u016fsob\u00ed Zipsydon p\u0159ib\u00edr\u00e1n\u00ed na v\u00e1ze?<\/h3>\n

      M\u00e9n\u011b ne\u017e jin\u00e9 atypick\u00e9 antipsychotika \u2014 ziprasidon je jedn\u00edm z nejm\u00e9n\u011b metabolicky zat\u011b\u017euj\u00edc\u00edch antipsychotik, spolu s aripiprazolem a lurasidonem. Mnoho pacient\u016f nezaznamen\u00e1 v\u00fdznamn\u00e9 p\u0159ib\u00edr\u00e1n\u00ed na v\u00e1ze. To je hlavn\u00ed d\u016fvod, pro\u010d se ziprasidon vol\u00ed m\u00edsto olanzapinu nebo kvetiapinu.<\/p>\n

      Je Zipsydon bezpe\u010dn\u011bj\u0161\u00ed ne\u017e jin\u00e1 atypick\u00e1 antipsychotika pro srdce?<\/h3>\n

      Ne \u2014 naopak. Ziprasidon m\u00e1 nejvy\u0161\u0161\u00ed \u00fa\u010dinek na prodlou\u017een\u00ed QT intervalu mezi b\u011b\u017en\u011b pou\u017e\u00edvan\u00fdmi atypick\u00fdmi antipsychotiky. Pacienti s p\u0159edchoz\u00edm prodlou\u017een\u00edm QT intervalu, ned\u00e1vn\u00fdm infarktem myokardu nebo nekompenzovan\u00fdm srde\u010dn\u00edm selh\u00e1n\u00edm by nem\u011bli u\u017e\u00edvat ziprasidon.<\/p>\n

      Co je prodlou\u017een\u00ed QT intervalu a pro\u010d je d\u016fle\u017eit\u00e9?<\/h3>\n

      QT interval je \u010das, kter\u00fd pot\u0159ebuje elektrick\u00fd syst\u00e9m srdce k obnov\u011b mezi \u00fadery, m\u011b\u0159en\u00fd na EKG. Prodlou\u017een\u00fd QT interval zvy\u0161uje riziko nebezpe\u010dn\u00e9 arytmie (torsades de pointes), kter\u00e1 m\u016f\u017ee zp\u016fsobit n\u00e1hlou srde\u010dn\u00ed smrt. V\u011bt\u0161ina prodlou\u017een\u00ed QT intervalu je asymptomatick\u00e1, ale riziko je re\u00e1ln\u00e9 p\u0159i kumulativn\u00edch \u00fa\u010dinc\u00edch jin\u00fdch l\u00e9k\u016f prodlu\u017euj\u00edc\u00edch QT interval nebo p\u0159i n\u00edzk\u00e9 hladin\u011b drasl\u00edku \/ ho\u0159\u010d\u00edku.<\/p>\n

      Mohu u\u017e\u00edvat Zipsydon s jin\u00fdmi antidepresivy?<\/h3>\n

      Ano \u2014 ziprasidon se n\u011bkdy p\u0159id\u00e1v\u00e1 k SSRI \/ SNRI u l\u00e9\u010debn\u011b rezistentn\u00ed deprese. Vyhn\u011bte se kombinac\u00edm s citalopramem > 20 mg, methadonem nebo fluorochinolony \u2014 aditivn\u00ed \u00fa\u010dinek na QT interval.<\/p>\n

      Zp\u016fsobuje Zipsydon sexu\u00e1ln\u00ed ne\u017e\u00e1douc\u00ed \u00fa\u010dinky?<\/h3>\n

      M\u00e9n\u011b ne\u017e risperidon \u2014 ziprasidon zp\u016fsobuje minim\u00e1ln\u00ed hyperprolaktin\u00e9mii. Sexu\u00e1ln\u00ed ne\u017e\u00e1douc\u00ed \u00fa\u010dinky jsou na molekul\u00e1rn\u00ed \u00farovni vz\u00e1cn\u00e9, ale z\u00e1kladn\u00ed psychiatrick\u00e9 onemocn\u011bn\u00ed a dal\u0161\u00ed l\u00e9ky \u010dasto p\u0159isp\u00edvaj\u00ed.<\/p>\n

      Je Zipsydon bezpe\u010dn\u00fd v t\u011bhotenstv\u00ed?<\/h3>\n

      Omezen\u00e9 \u00fadaje \u2014 nen\u00ed l\u00e9kem prvn\u00ed volby. Pokud se pokra\u010duje u z\u00e1va\u017en\u00e9ho du\u0161evn\u00edho onemocn\u011bn\u00ed, je nutn\u00e1 individu\u00e1ln\u00ed diskuse o rizic\u00edch a p\u0159\u00ednosech s p\u0159edepisuj\u00edc\u00edm l\u00e9ka\u0159em.<\/p>\n

      Mohu p\u00edt alkohol p\u0159i u\u017e\u00edv\u00e1n\u00ed Zipsydonu?<\/h3>\n

      Vyhn\u011bte se \u2014 zvy\u0161uje sedaci. T\u011b\u017ek\u00e1 konzumace alkoholu tak\u00e9 zvy\u0161uje riziko prodlou\u017een\u00ed QT intervalu.<\/p>\n

      Jak by m\u011bl b\u00fdt Zipsydon skladov\u00e1n?<\/h3>\n

      Skladujte p\u0159i 15\u201330 \u00b0C v p\u016fvodn\u00edm blistru, chr\u00e1n\u011bno p\u0159ed vlhkost\u00ed a slune\u010dn\u00edm sv\u011btlem. Uchov\u00e1vejte mimo dosah d\u011bt\u00ed.<\/p>\n

      Zdravotn\u00ed upozorn\u011bn\u00ed:<\/strong> Informace na t\u00e9to str\u00e1nce jsou ur\u010deny dosp\u011bl\u00fdm u\u017e\u00edvaj\u00edc\u00edm p\u0159edepsan\u00e9 psychiatrick\u00e9 l\u00e9ky a nenahrazuj\u00ed individu\u00e1ln\u00ed l\u00e9ka\u0159skou p\u00e9\u010di. Antidepresiva, antipsychotika a p\u0159\u00edbuzn\u00e9 l\u00e9ky mohou interagovat s jin\u00fdmi l\u00e9ky, alkoholem a st\u00e1vaj\u00edc\u00edmi zdravotn\u00edmi stavy. Jak\u00e9koli nov\u00e9 l\u00e9ky, zm\u011bnu d\u00e1vkov\u00e1n\u00ed nebo pl\u00e1novan\u00e9 vysazen\u00ed konzultujte s kvalifikovan\u00fdm l\u00e9ka\u0159em. Pokud se u v\u00e1s objev\u00ed sebevra\u017eedn\u00e9 my\u0161lenky, m\u00e1nie, t\u011b\u017ek\u00e1 akathisie, p\u0159\u00edznaky serotoninov\u00e9ho syndromu (vysok\u00e1 hore\u010dka, zmatenost, svalov\u00e1 ztuhlost, zrychlen\u00fd srde\u010dn\u00ed tep) nebo neuroleptick\u00fd malign\u00ed syndrom, vyhledejte okam\u017eit\u011b l\u00e9ka\u0159skou pomoc.<\/div>\n

      <\/p>\n

      Souvisej\u00edc\u00ed alternativy<\/h3>\n

      Dal\u0161\u00ed produkty v Chronick\u00e1 onemocn\u011bn\u00ed<\/strong> kter\u00e9 z\u00e1kazn\u00edci tak\u00e9 prohl\u00ed\u017eej\u00ed:<\/p>\n